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CONCLUSION:
Does improvement in RRT survival only reflect
better survival in the general population?
► Excess mortality (EM): mortality in RRT 
patients minus expected mortality in the 
matched general population
► Data from 280,075 incident adult RRT 
patients from 12 European countries
Data from the ERA-EDTA Registry was examined for trends in excess mortality in 
European adults on kidney replacement therapy.
Survival on dialysis has improved more than in 
the general population, especially for 
atheromatous CVD. In transplant recipients, the 




Relative EM risk per 5 year (95%CI)
Dialysis Transplant
All-cause 0.86 (0.85 - 0.86) 1.16 (1.07 - 1.26)
Atheromatous CVD 0.72 (0.70 - 0.74) 1.29 (0.97 - 1.73)
Non-atheromatous CVD 0.90 (0.88 - 0.92) 1.00 (0.80 - 1.23)
Infections 0.90 (0.87 - 0.92) 0.99 (0.86 - 1.14)
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Data from the ERA-EDTA Registry was examined for trends in excess 
mortality in European adults on kidney replacement therapy. 
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The objective of this study was to investigate whether the improvement in survival seen in 
patients on kidney replacement therapy reflects the enhanced survival of the general 
population. Patient and general population statistics were obtained from the European Renal 
Association-European Dialysis and Transplant Association (ERA-EDTA) Registry and the 
World Health Organization databases, respectively. Relative survival models were composed 
to examine trends over time in all-cause and cause-specific excess mortality, stratified by age 
and modality of kidney replacement therapy, and adjusted for sex, primary kidney disease 
and country. In total, 280,075 adult patients started kidney replacement therapy between 2002 
and 2015. The excess mortality risk in these patients decreased by 16% per five years 
(relative excess mortality risk (RER)) 0.84; 95% confidence interval 0.83-0.84). This 
reflected a 14% risk reduction in dialysis patients (RER 0.86; 0.85-0.86), and a 16% increase 
in kidney transplant recipients (RER 1.16; 1.07-1.26). Patients on dialysis showed a decrease 
in excess mortality risk of 28% per five years for atheromatous cardiovascular disease as the 
cause of death (RER 0.72; 0.70-0.74), 10% for non-atheromatous cardiovascular disease 
(RER 0.90; 0.88-0.92) and 10% for infections (RER 0.90; 0.87-0.92). Kidney transplant 
recipients showed stable excess mortality risks for m st causes of death, although it did 
worsen in some subgroups. Thus, the increase in survival in patients on kidney replacement 
therapy is not only due to enhanced survival in the general population, but also due to 
improved survival in the patient population, primarily in dialysis patients.  
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Patients with end-stage kidney disease (ESKD) are at a high risk of death. Even after starting renal 
replacement therapy (RRT), half of the patients will die within 5 years.1 On the other hand, analyses of 
registry data have shown that patient survival on RRT has moderately improved over the last 
decades.2-4 Part of this increase may reflect the overall increase in survival of the general population. 
One way of comparing survival of the RRT population with that of the general population is by 
applying time-dependent relative survival models. For the United States RRT population, Foster et al. 
have recently applied these models to examine trends in excess mortality over time.5 Excess mortality 
was defined as the mortality in the RRT population minus the expected mortality in the general 
population, matched for age, ethnicity, and sex. Their results showed that between 1995 and 2013 the 
excess risk of all-cause mortality among patients on RRT decreased for all age categories.5 The 
results of this study, however, may not be generalizable to the European RRT population due to 
differences in case-mix, such as comorbidities, primary kidney disease distribution, and ethnicity, and 
differences in health insurance status, economic incentives and patient survival.1,6-10 
Changes in excess mortality may differ by cause of death. In the general population, there 
was a decrease in death rates for malignancies and ischemic heart disease over the last decade, 
whereas a small increase was observed for infections.11,12 Simultaneously, Pippias et al. showed that 
the risk of death in RRT patients decreased for cardiovascular diseases and infections, while among 
patients aged 65 years and older mortality due to malignancies increased.4 However, Pippias et al. 
did not examine trends over time in cause-specific mortality in patients on RRT in relation to mortality 
trends in the general population. 
Therefore, using the European Renal Association-European Dialysis and Transplant 
Association (ERA-EDTA) Registry database, we aimed to examine trends over time in excess all-
cause mortality and excess cause-specific mortality in patients on RRT, by subgroups of age and 
RRT modality. If we could show a larger improvement in the survival of RRT patients than in the 
general population, hence a decrease in excess mortality, this potentially indicates a better treatment 








In total, 280,075 adult patients initiated RRT between 1 January 2002 and 31 December 2015, 
contributing 1,031,390 person-years on RRT to the study, including 729,654 person-years on dialysis 
and 301,422 person-years with a functioning kidney transplant. Table 1 shows the patient 
characteristics by calendar period and age group. Most patients were male (63%) and diabetes 
mellitus was the most common cause of ESKD (21%). The case-mix of the study population when 
censored after 5 years of follow-up was similar to the total study population (data not shown). Even 
after censoring, the percentage of kidney transplant recipients slightly increased over time (Table 1). 
When compared to the uncensored results, the decrease in observed mortality rates were less 
pronounced in censored RRT patients. In the subgroup of transplant recipients, the increase in 
observed mortality rates almost disappeared after censoring at 5 years of follow-up (Table 1).  
 
Absolute excess mortality rate for all-causes of death 
Figure 1 demonstrates that adult patients on RRT had a decrease in the absolute all-cause excess 
mortality rate from 136 extra deaths per 1,000 person-years in 2007 to 116 extra deaths per 1,000 
person-years in 2015. In dialysis patients, the excess mortality rate decreased from 165 extra deaths 
per 1,000 person-years to 148 extra deaths per 1,000 person-years, whereas in patients with a 
functioning kidney transplant the excess mortality was low and constant at approximately 7 extra 
deaths per 1,000 person-years. Excess mortality rates were about 20 times higher in patients on 
dialysis compared with transplanted patients, but with decreasing mortality in dialysis patients this 
ratio decreased slightly over time (Figure 1). In patients on hemodialysis (HD) between 2007 and 
2015 the excess mortality rate decreased from 178 extra deaths per 1,000 person-years to 154 extra 
deaths per 1,000 person-years, whereas in patients on peritoneal dialysis (PD) it fluctuated around 
108 extra deaths per 1,000 person-years (Figure S1). For transplant recipients the excess mortality 
rate was stable over time at approximately 9 extra deaths per 1,000 person-years for deceased donor 
transplants and 3 extra deaths per 1,000 person-years for living donor transplants (data not shown). 
Table S1 shows the observed and expected numbers of deaths, and crude observed and 
excess mortality rates by age and calendar year. Figure 2 shows the age-stratified absolute excess 
mortality rates for all patients on RRT, and for patients on dialysis and with a functioning kidney 




on RRT, the strongest decrease in excess mortality rate was observed in patients aged 65 years and 
older, with more modest reduction in younger patients. In patients on dialysis, the excess mortality 
rate mainly decreased in older patients, while in transplant recipients it remained similar over time in 
all age groups. To enable comparison with the results from the US5, Figure S2 shows the age-
stratified absolute excess mortality rates for RRT patients using the age categories 25-44, 45-64 and 
65 and over. 
 
Absolute excess mortality rate for specific causes of death 
Table S2 displays the different categories of causes of death. For the analyses by cause of death, 
data from 186,371 patients (66.5% of total) was included. In patients on RRT, the highest excess 
mortality rate was found for non-atheromatous cardiovascular diseases (CVD) and the lowest rate for 
malignancies, whereas over time the largest decrease was observed for atheromatous CVD (Figure 
3). In dialysis patients the highest excess mortality rate was observed for non-atheromatous CVD 
(Figure 3), this was the case for both HD and PD patients (Figure S3). In the total group of dialysis 
patients, all cause-specific excess mortality rates decreased over time, particularly for atheromatous 
CVD. This was also true for HD patients, whereas PD patients showed a downward trend for 
atheromatous CVD, no change for infections, and an upward trend for non-atheromatous CVD. In 
kidney transplant recipients the highest excess mortality rate was observed for infections (Figure 3). 
Nevertheless, the cause-specific excess mortality rates seemed to be low and stable over time. 
 
Relative excess mortality risk for all-causes of death 
Table 2 shows the unadjusted and adjusted all-cause relative excess mortality risk (RER) in the total 
adult RRT population, as well as stratified by age and RRT modality. The unadjusted and adjusted 
results were similar. The adjusted RER in patients on RRT was 0.84, 95% confidence interval (CI) 
0.83-0.84), implying that the excess mortality risk decreased by 16% for any 5-year interval between 
2002 and 2015. We observed a similar decrease in excess mortality risk in males and females on 
RRT, RER 0.84 (95%CI 0.83-0.85) and 0.83 (95%CI 0.82-0.84), respectively. Although the excess 
mortality risk in RRT patients decreased within all age groups, the magnitude of the reduction differed, 




variations in RER were observed between the different countries participating in this study (p<0.001), 
however, all countries showed a decreasing trend (data not shown). 
The trend in excess mortality risk also differed by RRT modality (p<0.001). In patients on 
dialysis the excess mortality risk decreased by 14% (RER 0.86; 95%CI 0.85-0.86) per 5 years, 
whereas it increased by 16% (RER 1.16; 95%CI 1.07-1.26) per 5 years in kidney transplant recipients 
(Table 2). For transplant recipients with a deceased donor transplant the excess mortality risk 
increased by 18% (1.18; 95%CI 1.08-1.30). In patients with a living donor transplant the number of 
deaths was too small to perform any further analyses. 
Dialysis patients showed a decrease in excess mortality risk in all age groups, ranging from 
9% for patients aged 20-44 years to 16% for patients aged 75 years and above. Similar trends were 
found for HD patients, whereas in PD patients both the overall excess mortality risk as well as the 
age-specific excess mortality risk remained stable over time (Table 2). In kidney transplant recipients 
the excess mortality risk remained stable for patients younger than 65 years but increased with 47% 
per five years for patients aged 65 years and older (Table 2). In a sensitivity analysis, including the 
date of first transplantation as starting point in transplant recipients, the excess mortality risk 
increased with 7% (RER 1.07; 95%CI 1.00-1.15) instead of 16% per five years. In patients aged 65 
years and older, the excess mortality risk increased with 38% (RER 1.38; 95%CI 1.22-1.57) instead of 
47%. 
Similar trends were observed before and from 2010 onwards (Table S3). The reduction in 
excess mortality risk in patients on RRT and the subgroup on dialysis became less prominent after 
2010, while the increase in excess mortality risk in transplant recipients became stronger and only 
reached statistical significance after 2010.  
 
Relative excess mortality risk for specific causes of death 
Table 3 shows that between 2002 and 2015 there was a decrease in the cause-specific excess 
mortality risk in adult RRT patients of 29% per five years for atheromatous CVD, 11% for non-
atheromatous CVD, 12% for infections, and 6% for malignancies. Across all age groups, the excess 
mortality risk declined over time for virtually all causes of death, although there was more uncertainty 





In dialysis patients, the excess mortality risk decreased over time for all causes of death, with 
the largest decrease for atheromatous CVD (Table 3). Also, HD patients showed a decrease in 
excess mortality risk for all causes of death, whereas in PD patients the risk decreased for 
atheromatous CVD and increased for non-atheromatous CVD (Table 3). In dialysis patients younger 
and older than 65 years, the strongest decrease in excess mortality risk was found for atheromatous 
CVD, whereas no statistically significant effect was found for malignancies in both age groups (Table 
S5). In kidney transplant recipients, the excess mortality risk remained stable for atheromatous CVD, 





Among 280,075 adult European patients starting RRT between 2002 and 2015, the all-cause excess 
mortality relative to the general population decreased with advancing calendar year in all age groups, 
suggesting that enhanced survival observed in patients on RRT is not only due to the better survival 
in the general population, but also due to an additional improvement in survival of the RRT population. 
Although the same methods were applied in the current study as Foster et al. used in a study 
carried out in the US,5 we found lower excess mortality rates for RRT patients in Europe. For 
example, in RRT patients aged 65 years and older, we observed an excess mortality rate of 206 extra 
deaths per 1,000 person-years in 2007 compared with 241 extra deaths per 1,000 person-years in the 
US (Figure S2).5 This difference may be due to differences in referral patterns, patient population and 
clinical practice.13-15 For example, the proportion of diabetes and hypertension as primary kidney 
disease is higher among RRT patients in the US, whereas the proportion of RRT patients with 
glomerulonephritis is higher in Europe.5 As the US had a higher excess mortality rate, changes in the 
number and severity of comorbidities may have had a larger effect in the US RRT population because 
there was more room for improvement. Nonetheless, trends in all-cause excess mortality for RRT 
patients in Europe were similar to those in the US.5 Both our study and the one by Foster et al. 
showed that within the youngest age group the greatest relative benefit over time was experienced as 
the relative excess mortality risk for this age group decreased most. However, from the perspective of 




mortality risk within the older age groups decreased less than in the youngest age group, the absolute 
excess mortality rate was many times higher, resulting in a much more prominent decrease in 
absolute excess mortality rates over time in older than in younger patients on RRT. 
We observed a stronger decrease in excess mortality risk for the total RRT population than in 
the dialysis population. This may be explained by a higher percentage of RRT patients receiving a 
kidney transplant over time. The mortality rate in kidney transplant recipients was lower than in 
dialysis patients. With more patients receiving a transplant over time, the total RRT excess mortality 
may decline more rapidly than that in the dialysis population.  
 
Trends in dialysis patients 
The observed decrease in absolute excess mortality rate in RRT patients was mainly due to the 
reduced rate in HD patients. Changes in clinical practice and uptake of clinical guidelines may have 
contributed to the improved survival of HD patients.16-18 Work by Tentori et al. showed that over time 
most European countries included in the Dialysis Outcomes and Practice Patterns Study (DOPPS) 
had a longer HD session time, which was associated with a lower mortality risk.19,20 Additionally, a 
decrease in interdialytic weight gain, as shown from phase 2 to 5 in the DOPPS study, may have led 
to a reduction in intradialytic hypotensive episodes, thereby contributing to the enhanced survival.21 
The lack of improvement of the excess mortality risk in PD patients may be due to the lower 
excess mortality rates, leaving less room for improvement over time. In addition, the time on PD 
before switching to another modality is relatively short for most PD patients. As a consequence, PD 
mortality primarily reflects short-term mortality, while in HD patients the follow-up is usually 
substantially longer, which may explain the greater survival improvement over time. 
In our cause-specific analyses, we observed the highest excess mortality rate in dialysis 
patients for CVD and infections and the lowest rates for malignancies, which is in line with previous 
studies on cause-specific mortality in dialysis patients.22,23 Both HD and PD patients showed a 
decrease in excess mortality for atheromatous CVD, and previous studies in Europe, the US, 
Australia and New-Zealand have also observed a decrease in cardiovascular mortality in dialysis 
patients over time.4,24-26 The fact that especially the number of deaths due to atheromatous CVD is 
decreasing over the last decades might be considered surprising when taking into account the 




of excess cardiovascular mortality in this patient group, the observed decrease may be explained by 
multiple changes instead of one single intervention. Ceretta et al.31 showed that in Europe between 
2005 and 2014, the percentage of patients with ischemic heart disease as a comorbidity at the start of 
RRT decreased indicating that patients start dialysis in better cardiovascular health, which may have 
contributed to the improved survival observed in this study. Furthermore, better management of 
dialysis patients with myocardial infarction or stroke in the last decades may partly explain the 
decrease in excess atheromatous CVD mortality. In addition, the implementation of the KDIGO 
clinical practice guideline on chronic kidney disease-mineral and bone disorder in 2009 led to a higher 
awareness of disturbances in calcium and phosphorus metabolism.32 As a consequence, vascular 
calcification in dialysis patients might be delayed or even prevented.33,34 
Although less prominent than for mortality due to atheromatous CVD, also a decrease in 
excess mortality due to infections was observed in patients on HD. This may be the consequence of 
better prevention of infections in HD patients.35-37 
 
Trends in patients with a functioning kidney transplant 
We observed a very low excess mortality rate of 7 extra deaths per 1,000 person-years in patients 
with a functioning kidney transplant when compared to the general population. However, in contrast to 
the study by Foster et al.,5 we found a statistically significant increase in excess mortality risk, 
particularly in older patients. Even after correcting for the increase in kidney transplantation rate over 
time by including the date of transplantation as starting point in the RER models, we still observed an 
increase in excess mortality risk for transplant recipients. It should be noted that due to the low 
excess mortality rate in transplant patients, small changes in the absolute mortality rate may have 
resulted in a large effect on the RER. Moreover, during our study period the mortality rate in the 
general population decreased, whereas the mortality rate in kidney transplant patients remained 
stable or slightly increased, contributing to an increase in excess mortality. The lack of improvement 
of the mortality rate in transplant patients may be explained by the increased acceptance of older 
patients for kidney transplantation,38 as well as by greater acceptance of older and marginal kidney 
donors.39 
In kidney transplant recipients, the excess mortality remained stable over time for nearly all 




malignancies. In our all-cause sensitivity analyses, we observed that the increased RER in transplant 
recipients became stronger and only reached statistical significance after 2010. Given that cause-
specific excess mortality risk for infections and malignancies either did not change or worsened, we 
hypothesize that higher burden of immunosuppression among the transplant recipients in more recent 
years may have reduced the rejection rates, but at the expense of a greater risk of infections and 
malignancies. However, we could not find any confirmation of this notion in the literature. In addition, 
as mentioned previously, small changes in the absolute mortality rates may have a large relative 
effect if the excess mortality rates are low. The absolute excess mortality rates for malignancies 
fluctuated around zero, with negative excess mortality rates of approximately -0.4 per 1000 person-
years before 2012 and positive rates after 2012 (around 0.4 per 1000 person-years), resulting in a 
significant increase in excess mortality risk. This finding suggests that the observed increase in 
excess mortality due to malignancies in kidney transplant recipients is the result of declining mortality 
rates in the general population.11 
 
Strengths and limitations 
The main strength of this study is the inclusion of a large cohort of over 280,000 patients on RRT from 
12 European countries, over a 14 year time period. Another strength is the use of RRT modality- 
specific analyses per calendar year as patients may have switched from one modality to another. A 
limitation of our study is that we were not able to include patients from Eastern European countries. 
Therefore, the results may not be generalizable to the whole of Europe. Furthermore, the study is 
limited by the lack of information on patient characteristics such as comorbidities, ethnicity, 
socioeconomic status, medication use, and patient GFR at the start of RRT and additional dialysis 
and transplantation characteristics such as the type of vascular access and KDPI. Another strength of 
our study was the ability to investigate cause-specific excess mortality. However, we were only able to 
include broad categories of causes of death with different data sources for the general population and 
the patient population. This may have led to some misclassification. A group featuring the other 
causes of death was added to the analyses in order to demonstrate that the other causes of death 
showed similar trends over time compared with the cause of death groups included in this study. 









Our study showed that between 2002 and 2015 the excess mortality decreased among patients on 
RRT in Europe, showing that the better survival observed in patients on RRT is not only due to the 
enhanced survival in the general population, but also due to an additional improved survival in the 
RRT population. In dialysis patients, especially on HD, the excess mortality decreased over time, 
which was predominantly the result of a decrease in atheromatous CVD as cause of death. Excess 
mortality due to non-atheromatous CVD and infections decreased to a lesser extent and future 
studies may focus on strategies to further reduce excess mortality due to these causes. Although the 
excess mortality risk increased over time in kidney transplant recipients, the absolute excess mortality 







The ERA-EDTA Registry collects individual patient data from national and regional renal registries in 
Europe that have data available on both dialysis and kidney transplant patients. Participating national 
and regional renal registries yearly provide a dataset to the ERA-EDTA Registry, containing at least 
the month and year of birth, sex, primary kidney disease, date of RRT onset, treatment modality at 
baseline and during follow-up, and date and cause of death of the patients in their coverage area. 
Details of the methods used for data collection and data processing can be found in the ERA-EDTA 
Registry Annual Report.1 Only data from registries with a full coverage of their country or region 
during the entire study period of 2002 to 2015 were included in the analyses. The study cohort 
consisted of patients aged 20 years and older who started RRT between 1 January 2002 and 31 




France (regions Auvergne, Limousin, Lorraine, Rhône-Alpes, together covering 16.5% of France), 
Greece, Iceland, the Netherlands, Norway and Sweden) and 12 regional renal registries (Dutch- and 
French-speaking Belgium, the Spanish regions of Andalusia, Aragon, Asturias, Basque country, 
Catalonia, Cantabria, Castile and Leon, and Valencia (together covering 61.4% of Spain), and UK 
England, Wales, and Scotland). In total, the registries contributing data to this study covered 119 
million Europeans, comprising approximately 47.5% of the Northwestern European population and 
30.6% of the Southern European population. In line with the study of Foster et al., patients who died 
on the date of first RRT (N=100, 0.04%) were excluded from the analyses and patients who received 
a third kidney transplant (N=111, 0.16%) were censored at the date of that transplantation.5 
 
General population 
Mortality data from the general population of the countries included in this study were obtained from 
the World Health Organization (WHO) and were used to calculate the mortality rates. The WHO 
provides mortality data (as number of deaths) coded according to the International Statistical 
Classification of Diseases and Related Health Problems (ICD) stratified by country, 5-year age group, 
sex, and calendar year. For each country, the number of deaths for each cause of death were 
obtained between 2002 and 2015, using ICD-9 or ICD-10 codes (Table S2).40,41 
 
Primary exposure and outcome variables 
The primary exposure was the calendar year of observation (time-varying, continuous variable). The 
primary outcome was all-cause excess mortality in patients on RRT. Furthermore, different groups 
were made for the cause specific excess mortality analyses, including CVD, infections and 
malignancies. CVD was subdivided into atheromatous CVD (myocardial ischemia and infarction, 
cerebrovascular diseases and mesenteric infarction) and non-atheromatous CVD (all other 
cardiovascular diseases), using the ICD-9 or ICD-10 codes for the general population and the ERA-
EDTA Registry cause of death codes for the RRT patients (Table S2).1,40 Patients from the Spanish 
regions Castile and Leon and Valencia, and those from UK England and Wales as well as France 
were excluded from the cause-specific mortality analyses since for these countries and regions the 






The SAS macro Lexis was used to split each patient’s observation into multiple intervals based on 
calendar year.42,43 Time zero was the date of first RRT. Patients were censored at the end of the 
study period (31 December 2015). For each patient, the current age and RRT modality (HD, PD or 
kidney transplantation) were determined for each calendar year based on the age and modality at the 
first of July, leading to a dynamic dataset as patients were followed over time.  
 
Absolute excess mortality rate  
Absolute excess mortality rate (deaths per 1,000 person-years) for each age interval in each calendar 
year was defined as the observed number of deaths in the RRT population minus the expected 
number of deaths (based on the mortality rate in the general population), divided by the number of 
RRT person-years, multiplied by 1,000. The expected number of deaths was calculated as the five-
year age-, sex-, and calendar year–specific mortality rates in the general population multiplied by the 
number of RRT person-years within the same age-, sex- and calendar year. 
During the study period, in Europe, the proportion of incident and prevalent patients on RRT 
changed over time, with an increasing percentage of prevalent patients on RRT. This may result in a 
‘healthier’ cohort in the more recent calendar years, since the most severely ill patients will have died 
in the first years after initiating RRT. To maintain a stable proportion of incident and prevalent RRT 
patients in the absolute excess mortality rate analyses, patients on RRT were censored after 5 years 
of follow-up. As a result, the proportion of incident and prevalent RRT patients became stable from 
2007 onwards, hence, the absolute excess mortality rate figures start from this year.  
 
 
Relative excess mortality risk 
Time-dependent relative survival models with time-varying covariates were used to estimate the RER 
in RRT patients associated with advancing calendar year. Relative survival models assume constant 
hazards in each interval, which implies a Poisson process for the number of deaths in each 
interval.44,45 We assumed a constant hazard within each 1-year interval. The SAS procedure 




RER models were made for all RRT patients and an interaction term between RRT modality 
and calendar year was used to obtain model estimates separately for dialysis patients and kidney 
transplant recipients. Unadjusted models included current age, current calendar year, and follow-up 
year, whereas adjusted models further included sex, primary kidney disease, and country. One of the 
advantages of the RER models is that they account for patient-specific follow-up year by including this 
as a factor in the models. As a consequence, complete follow-up data could be used for these 
analyses, and therefore, patients were not censored after 5 years of follow-up in the RER analyses. 
To determine whether changes in excess mortality risk over time differed by age, the age group-
specific models included an interaction between current age group (20–44, 45–64, 65-74 and ≥75 
years) and calendar year. For the change in excess mortality risk in different age groups in the 
modality-specific models, an interaction term for time-varying RRT modality, by age group, and by 
calendar year was added. Finally, RER models were made with an interaction term between dialysis 
modality and transplant type and calendar year to obtain model estimates for HD or PD patients and 
for kidney transplant recipients with a graft from a living or deceased donor separately. Although the 
models provided RER estimates for a 1-year interval in calendar year, these were scaled up to the 
fifth power to obtain RER estimates for a 5-year interval in calendar year. 
Sensitivity analyses were performed to investigate whether a country or study period had an 
effect on the trends in excess mortality. In addition, to investigate the influence of the increased 
kidney transplantation rate over time, a sensitivity analysis was performed using the date of first 
transplantation as the starting point in the RER models. All analyses were performed using SAS 
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Tables and figures 
 
Table 1.  Patient characteristics by calendar period and age group among European adults who initiated RRT between 2002 and 2015. 
 Total Calendar year Age group (years) 
Total study population   2002-2006 2007-2009 2010-2012 2013-2015 20-44 45-64 65-74 75+ 
Person-years          
    On RRT 1,031,390 168,728 223,459 290,777 348,427 154,586 364,567 251,433 260,804 






































Age (%)          
    20-44 years  15,1 15,4 15,2 14,5     
    45-64 years  33,5 34,8 35,8 36,2     
    65-74 years  26,6 24,2 23,4 24,2     
    75+ years  24,8 25,6 25,6 25,0     
Sex (%)          
    Female 37.5 38.5 37.7 37.4 37.0 38.2 36.9 36.5 38,9 
    Male 62.5 61.5 62.3 62.6 63.0 61.8 63.1 63.5 61,1 
Primary kidney disease (%)          
    Diabetes mellitus 21.0 22.1 21.6 20.8 20.2 15.2 22.4 25.3 18.3 
    Renal vascular disease 3.9 4.6 4.4 3.9 3.2 0.6 1.8 4.8 7.8 
    Hypertension 11.4 11.6 11.4 11.3 11.3 5.7 8.3 12.2 18.2 
    Polycystic kidney disease 8.8 7.5 8.4 9.0 9.6 5.3 14.9 7.4 3.4 
    Glomerulonephritis/sclerosis 15.8 14.5 15.5 16.0 16.4 26.9 18.5 12.6 8.4 
    Pyelonephritis 6.7 6.9 6.9 6.6 6.5 10.8 5.8 5.7 6.4 
    Other 15.2 15.2 14.8 15.1 15.5 19.8 14.1 15.2 13.9 
    Unknown 16.4 16.9 16.5 16.5 16.1 14.6 12.9 16.0 22.8 
    Missing 0.9 0.8 0.6 0.7 1.2 1.1 1.0 0.8 0.6 
Number of deaths           
    All RRT 143,778 30,241 33,362 38,236 41,939 3,317 25,456 39,859 75,146 




    Kidney transplant 5,556 250 804 1,670 2,832 396 2,167 2,166 827 
Observed absolute mortality rate per 
1,000 person-years (95%CI) 
 
        






















































Censored study population           
Person-years          
    On RRT 770,045 168,728 191,076 201,122 209,119 108,418 258,091 192,915 210,621 






































Number of deaths          
    All RRT 118,272 30,241 29,806 29,165 29,060 2,701 20,636 33,099 61,836 
    Dialysis, all modalities 116,340 29,986 29,310 28,636 28,408 2,511 19,765 32,393 61,671 
    Kidney transplant 1,923 250 493 528 652 190 867 705 161 
Observed absolute mortality rate per 
1,000 person-years (95%CI) 
         






























































Figure 1. Absolute excess mortality rate in European adults who initiated RRT between 2002 and 
2015, overall and by RRT modality. Patients were censored after 5 years of follow-up, resulting in 
770,045 person-years (PY) on RRT, of which 621,932 PY were spent on dialysis and 147,810 PY with 
a functioning kidney transplant. Censoring the patients’ follow-up after 5 year led to a stable proportion 
of incident and prevalent patients on RRT from 2007; therefore the results are shown from 2007 









Figure 2.  Absolute all-cause excess mortality rate in European adults who initiated RRT between 2002 and 2015 by age group. Patients were censored after 
5 years of follow-up, resulting in 770,045 person-years (PY) on RRT (left panel), of which 621,932 PY were spent on dialysis (middle panel) and 147,810 PY 
with a functioning kidney transplant (right panel). Please, note the different scale on Y-axis. Censoring the patients’ follow-up after 5 year led to a stable 
proportion of incident and prevalent patients on RRT from 2007; therefore the results are shown from 2007 onwards. Due to the small number of patients with 
















Figure 3.  Absolute cause-specific excess mortality rate in European adults who initiated RRT between 2002 and 2015. In total, 186,110 patients on RRT were 
included. After censoring these patients at 5 years of follow-up, they contributed to the study with 504,845 person-years (PY) on RRT (left panel), of which 
410,603 PY were spent on dialysis (middle panel) and 94,214 PY with a functioning kidney transplant (right panel). Please, note the different scale on Y-axis. 
Censoring the patients’ follow-up after 5 year led to a stable proportion of incident and prevalent patients on RRT from 2007; therefore the results are shown 
from 2007 onwards. Due to the small number of patients with a functioning kidney transplant in the different cause of death groups, the yearly estimates show 

































Table 2.  Relative all-cause excess mortality risk per 5-year 
interval in calendar year for European adults who initiated RRT 
between 2002 and 2015, by RRT modality and age category. 
 Unadjusted RER a  
(95% CI) 
Adjusted RER b 
(95% CI) 
RRT 
All adults 0.84 (0.84 to 0.85) 0.84 (0.83 to 0.84) 
  20-44 years 0.79 (0.75 to 0.83) 0.76 (0.72 to 0.80) 
  45-64 years 0.80 (0.79 to 0.82) 0.80 (0.78 to 0.81) 
  65-74 years 0.83 (0.82 to 0.85) 0.84 (0.82 to 0.85) 
  75+ years 0.90 (0.89 to 0.91) 0.89 (0.87 to 0.90) 
Dialysis, all modalities c 
All adults 0.86 (0.86 to 0.87) 0.86 (0.85 to 0.86) 
  20-44 years 0.93 (0.88 to 0.98) 0.91 (0.87 to 0.96) 
  45-64 years 0.92 (0.90 to 0.93) 0.90 (0.89 to 0.92) 
  65-74 years 0.87 (0.86 to 0.89) 0.86 (0.85 to 0.88) 
  75+ years 0.85 (0.84 to 0.86) 0.84 (0.83 to 0.86) 
Hemodialysis c 
All adults 0.84 (0.83 to 0.85) 0.83 (0.82 to 0.84) 
  20-44 years 0.88 (0.83 to 0.93) 0.85 (0.80 to 0.90) 
  45-64 years 0.88 (0.86 to 0.90) 0.87 (0.85 to 0.89) 
  65-74 years 0.85 (0.84 to 0.86) 0.84 (0.82 to 0.85) 
  75+ years 0.83 (0.82 to 0.85) 0.83 (0.82 to 0.84) 
Peritoneal dialysis c,d  
All adults 1.01 (0.98 to 1.05) 1.01 (0.98 to 1.04) 
  20-44 years 1.04 (0.90 to 1.20) 1.04 (0.90 to 1.20) 
  45-64 years 0.98 (0.92 to 1.04) 0.99 (0.93 to 1.05) 
  65-74 years 1.01 (0.96 to 1.07) 1.01 (0.96 to 1.07) 
  75+ years 1.01 (0.95 to 1.06) 1.01 (0.95 to 1.06) 
Kidney transplant c 
All adults 1.21 (1.11 to 1.32) 1.16 (1.07 to 1.26) 
  20-44 yearsd 0.95 (0.77 to 1.17) 0.90 (0.73 to 1.11) 
  45-64 yearsd 1.07 (0.95 to 1.22) 1.01 (0.90 to 1.14) 
  65+ yearsd 1.53 (1.32 to 1.78) 1.47 (1.27 to 1.70) 
In the all-cause excess mortality risk analyses, all 280,075 RRT 
patients were included with a total follow-up time of 1,031,390 
person-years on RRT, of which 729,654 person-years were spent 
on dialysis and 301,422 person-years with a functioning kidney 
transplant. The interaction terms for year by age group, year by 
RRT modality and year by age group by RRT modality were all 
statistically significant (p=0.001). 
a Unadjusted models for all adults included follow-up, current age 
(as continuous variable) and current calendar year. Unadjusted 
models per age group included follow-up and current calendar 
year.  
b Adjusted models further included sex, primary kidney disease 
and country. 
c RRT modality was included in the model as an interaction term 
with current calendar year 
d Models from 2004 onwards due to the lack of power in the 
earlier calendar years. 
Abbreviations: RRT, renal replacement therapy; RER, relative 




Table 3.  Relative excess mortality risk per 5-year interval in calendar year for 
European adults who initiated RRT between 2002 and 2015, by RRT 
modality and cause of death. 
Cause of death  Unadjusted RER a  
(95% CI) 
Adjusted RER b 
(95% CI) 
RRT 
All-causes 0.84 (0.84 to 0.85) 0.84 (0.83 to 0.84) 
  Atheromatous CVD 0.71 (0.69 to 0.73) 0.71 (0.69 to 0.73) 
  Non-atheromatous CVD 0.89 (0.87 to 0.91) 0.89 (0.87 to 0.91) 
  Infections 0.88 (0.86 to 0.90) 0.88 (0.86 to 0.90) 
  Malignancies 0.99 (0.94 to 1.05) 0.94 (0.89 to 0.99) 
  Other causes 0.86 (0.84 to 0.88) 0.86 (0.84 to 0.89) 
Dialysis, all modalities c 
All-causes 0.86 (0.86 to 0.87) 0.86 (0.85 to 0.86) 
  Atheromatous CVD 0.73 (0.71 to 0.75) 0.72 (0.70 to 0.74) 
  Non-atheromatous CVD 0.91 (0.89 to 0.93) 0.90 (0.88 to 0.92) 
  Infections 0.90 (0.88 to 0.92) 0.90 (0.87 to 0.92) 
  Malignancies 1.00 (0.95 to 1.06) 0.95 (0.90 to 1.00) 
  Other causes 0.89 (0.86 to 0.91) 0.89 (0.87 to 0.91) 
Hemodialysis c 
All-causes 0.84 (0.83 to 0.85) 0.83 (0.82 to 0.84) 
  Atheromatous CVD 0.71 (0.68 to 0.73) 0.70 (0.67 to 0.72) 
  Non-atheromatous CVD 0.88 (0.86 to 0.90) 0.87 (0.85 to 0.90) 
  Infections 0.88 (0.86 to 0.90) 0.88 (0.85 to 0.90) 
  Malignancies 0.99 (0.94 to 1.05) 0.95 (0.90 to 1.00) 
  Other causes 0.86 (0.84 to 0.89) 0.87 (0.85 to 0.89) 
Peritoneal dialysis c,d  
All-causes 1.01 (0.98 to 1.05) 1.01 (0.98 to 1.04) 
  Atheromatous CVD 0.87 (0.79 to 0.95) 0.87 (0.79 to 0.95) 
  Non-atheromatous CVD 1.12 (1.04 to 1.20) 1.12 (1.04 to 1.20) 
  Infections 1.00 (0.93 to 1.07) 0.99 (0.92 to 1.07) 
  Malignancies 0.97 (0.43 to 2.21) e 
  Other causes 1.10 (1.00 to 1.20) 1.11 (1.02 to 1.22) 
Kidney transplant c,d  
All-causes 1.21 (1.11 to 1.32) 1.16 (1.07 to 1.26) 
  Atheromatous CVD 1.40 (1.00 to 1.98) 1.29 (0.97 to 1.73) 
  Non-atheromatous CVD 1.03 (0.82 to 1.28) 1.00 (0.80 to 1.23) 
  Infections 1.01 (0.88 to 1.16) 0.99 (0.86 to 1.14) 
  Malignancies 2.54 (1.53 to 4.24) 2.51 (1.35 to 4.68) 
  Other causes 1.25 (0.76 to 2.06) 1.09 (0.74 to 1.61) 
186,371 patients on RRT were included with a total follow-up time of 674,980 
person-years, of which 480,323 person-years were spent on dialysis and 
194,629 person-years with a functioning kidney transplant. 
a Unadjusted models included follow-up, current age (continuous) and 
current calendar year. 
b Adjusted models further included sex, primary kidney disease and country. 
c RRT modality was included in the model as an interaction term with current 
calendar year. 
d Models from 2004 onwards due to the lack of power in the earlier calendar 
years. 
e Lack of power, model fit questionable. 
Abbreviations: CVD, cardiovascular disease; RRT, renal replacement 










Figure S1 . Absolute excess mortality rate in European adults who initiated dialysis between 2002 and 
2015, by dialysis modality. Censoring the patients’ follow-up after 5 year led to a stable proportion of 




Table S1.  Person-years at risk, observed deaths, expected deaths, and absolute excess mortality 
rates among patients on RRT, by age category and calendar year. Patients were censored after 5 
years of follow-up to obtain a stable proportion of incident and prevalent RRT patients from 2007 
onwards. 
 
Abbreviations: RRT, renal replacement therapy; PY, person-years. 
 
 
Figure S2. Absolute excess mortality rate in European adults who initiated RRT between 2002 and 
2015, by age group. Censoring the patients’ follow-up after 5 year led to a stable proportion of incident 
and prevalent patients on RRT from 2007; therefore the results are shown from 2007 onwards. To 
enable comparison with the results from Foster et al., CJASN 20185, similar age groups are presented 
(25-44 years, 45-64 years and 65 years and older). 
 
 
Table S2.  Causes of death categories specified by codes from the ERA-EDTA Registry and the ICD-9 
and ICD-10 coding systems. 
 
 
Figure S3.  Absolute cause-specific excess mortality rate in European adults who initiated 
hemodialysis (left panel) or peritoneal dialysis (right panel) between 2002 and 2015. Censoring the 
patients’ follow-up after 5 year led to a stable proportion of incident and prevalent patients on RRT 
from 2007; therefore the results are shown from 2007 onwards. 
  
 
Table S3.  Relative excess mortality risk per 5-year interval in calendar year, by treatment modality and 
by age category for European adults who initiated RRT before and from 2010. 
 
a Unadjusted models for all adults included follow-up, current age (continuous variable) and current 
calendar year. Unadjusted models per age group included follow-up and current calendar year.  
b Adjusted models further included sex, primary kidney disease and country. 
c RRT modality was included in the model as an interaction term with calendar year.  
Abbreviations: RRT, renal replacement therapy; RER, relative excess mortality risk 
 
 
Table S4.  Relative excess mortality risk per 5-year interval in calendar year for European adults who 
initiated RRT between 2002 and 2015, by cause of death and age category. 
 
a Unadjusted models for all adults included follow-up, current age (continuous variable) and current 
calendar year. Unadjusted models per age group included follow-up and current calendar year.  
b Adjusted models further included sex, primary kidney disease and country. 








Table S5.  Relative excess mortality risk per 5-year interval in calendar year for European adults who 
initiated dialysis, all modalities, between 2002 and 2015, by cause of death and age category. 
 
Age group models from 2004 onwards due to lack of power in the earlier years. Broader age groups 
(20-64 years and 65+ years) were included to obtain enough power for the analyses. 
a Unadjusted models for all adults included follow-up, current age (continuous variable) and current 
calendar year. Unadjusted models per age group included follow-up and current calendar year.  
b Adjusted models further included sex, primary kidney disease and country. 
c Lack of power, model fit questionable.  
Abbreviations: CVD, cardiovascular disease; RER, relative excess mortality risk. 
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Figure 1. Absolute excess mortality rate in European adults who initiated RRT between 2002 and 2015, overall 
and by RRT modality. Patients were censored after 5 years of follow-up, resulting in 770,045 person-years (PY) on 
RRT, of which 621,932 PY were spent on dialysis and 147,810 PY with a functioning kidney transplant. Censoring 
the patients’ follow-up after 5 year led to a stable proportion of incident and prevalent patients on RRT from 2007; 
therefore the results are shown from 2007 onwards. RRT, renal replacement therapy. 
Figure 2. Absolute all-cause excess mortality rate in European adults who initiated RRT between 2002 and 2015 by age 
group. Patients were censored after 5 years of follow-up, resulting in 770,045 person-years (PY) on RRT (left panel), of 
which 621,932 PY were spent on dialysis (middle panel) and 147,810 PY with a functioning kidney transplant (right 
panel). Please, note the different scale on Y-axis. Censoring the patients’ follow-up after 5 year led to a stable proportion 
of incident and prevalent patients on RRT from 2007; therefore the results are shown from 2007 onwards. Due to the 
small number of patients with a functioning kidney transplant in the different age groups, the yearly estimates show a 
larger fluctuation. RRT, renal replacement therapy. 
Figure 3. Absolute cause-specific excess mortality rate in European adults who initiated RRT between 2002 and 2015. In 
total, 186,110 patients on RRT were included. After censoring these patients at 5 years of follow-up, they contributed to the 
study with 504,845 person-years (PY) on RRT (left panel), of which 410,603 PY were spent on dialysis (middle panel) and 
94,214 PY with a functioning kidney transplant (right panel). Please, note the different scale on Y-axis. Censoring the 
patients’ follow-up after 5 year led to a stable proportion of incident and prevalent patients on RRT from 2007; therefore the 
results are shown from 2007 onwards. Due to the small number of patients with a functioning kidney transplant in the 
different cause of death groups, the yearly estimates show a larger fluctuation. RRT, renal replacement therapy.
